New 'Living Drug' tested for Tough-to-Treat blood cancer
NCT ID NCT07185490
Summary
This early-stage study is testing a new type of treatment called IASO104, a CAR-T cell therapy, for patients with multiple myeloma that has come back or stopped responding to other treatments. Doctors will give patients a single infusion of their own genetically modified immune cells to see if it is safe and can help fight the cancer. The main goals are to find the best dose and check for side effects in about 40 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.